ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1206

Canakinumab Treatment Regimens In CAPS Patients

Ferdinand Hofer1, Theresa Endres1, Birgit Kortus-Goetze2, Norbert Blank3, Elisabeth Weissbarth-Riedel4, Catharina Schuetz5, Tilmann Kallinich6, Karoline Krause7, Christoph Rietschel8, Gerd Horneff9 and Jasmin B. Kuemmerle-Deschner10, 1Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, 2Klinik für Innere Medizin, Klinikum der Philipps-Universität Marburg, Marburg, Germany, 3University of Heidelberg, Heidelberg, Germany, 4Kinderrheumatologische Ambulanz, Universitätsklinikum Eppendorf, Hamburg, Germany, 5Klinik für Kinder und Jugendmedizin, Universitätsklinikum Ulm, Ulm, Germany, 6Charite, University Medicine Berlin, Berlin, Germany, 7Dept. of Dermatology and Allergy, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, Germany, Berlin, Germany, 8Kinder- und Jugendrheumatologie, Clementine-Kinderhospital, Frankfurt, Germany, 9Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 10University Hospital Tuebingen, Tuebingen, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Autoinflammatory Disease, canakinumab and treatment, IL-1, Muckle-Wells syndrome

  • Tweet
  • Email
  • Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases I: Autoinflammatory Syndromes

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Canakinumab is a recombinant monoclonal fully human antibody against Interleukin-1β and approved for the treatment of CAPS in many countries including Europe and the US. Current dose recommendations are 150mg (body weight  >40kg) respectively 2mg/kg body weight (15 to 40kg) every 8 weeks but yield insufficient response in some individuals, especially in children and patients with severe phenotypes1.

In this study we analyzed the response to daily practice (in contrast to trial condition) canakinumab treatment regimens in CAPS patients with focus on age, mutation and clinical presentation and the necessity and effect of dose adjustment.

Methods:

An observational national multicenter study was conducted. CAPS patients were included if they received at least two doses of canakinumab. Data included information regarding demographics, treatment, clinical disease activity and inflammatory markers (including SAA, CRP, ESR, IL-6). Response to treatment was assessed using CAPS-disease activity scores, CRP and/or SAA levels.

Results:

A cohort of 68 patients with CAPS was analyzed. Median age was 25.4 years (range 22 months to 73 years). When treatment was initiated, 27 patients had been younger than 18 years. The most frequent mutations were R260W, A439V, E311K, V198M, Q703K and most patients showed MWS or FCAS/MWS phenotype (3 patients with NOMID, 4 with MWS/NOMID).

The median treatment duration was 855 days (range: 28-1973 days). In 39 patients (57%) full response was sustained until the next scheduled drug application (34% (23 patients) partial remission). With standard treatment 21 patients (31%) achieved full response. In 30 patients (44%) canakinumab dose and/or application interval was increased above the standard regimen (2/3 NOMID, 3/4 MWS/NOMID).

Neither laboratory parameters nor clinical disease activity at the beginning of treatment were able to predict the necessity to adjust treatment regimen. Two serious adverse events were reported (severe infection, osteonecrosis), mild and moderate adverse events were mostly upper respiratory tract infections but almost no injection site reactions.

Conclusion:

Most CAPS patients achieve full remission with canakinumab. However, almost 50% of patients, particularly children, require dose adjustment. Full remission by dose increase was achieved without an increased rate of adverse events. Individual adjustment of therapy should be performed as needed as predictive parameters are lacking.


Disclosure:

F. Hofer,
None;

T. Endres,
None;

B. Kortus-Goetze,
None;

N. Blank,
None;

E. Weissbarth-Riedel,
None;

C. Schuetz,
None;

T. Kallinich,
None;

K. Krause,
None;

C. Rietschel,
None;

G. Horneff,

AbbVie, Pfizer, Roche,

2,

AbbVie, Novartis, Pfizer, Roche,

8;

J. B. Kuemmerle-Deschner,

Novartis Pharmaceutical Corporation,

2,

Novartis Pharmaceutical Corporation,

5.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/canakinumab-treatment-regimens-in-caps-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology